Literature DB >> 333492

The influence of propranolol on the exposure in vivo of agoraphobics.

J Hafner, F Milton.   

Abstract

This study examines the influence of 40 mg of propranolol on agoraphobics throughout 5-hour periods of exposure in vivo on 3 alternate days. Twenty-three patients were studied using a double-blind parallel design and 19 followed up for 3 months. The propranolol group spent significantly less time than the placebo group travelling alone in the month after treatment, and had improved significantly less on a measure of general symptoms at 3 months. The adverse influence of propranolol on treatment outcome appeared mainly due to a waning effect in the last hour of exposure. Attempts to measure coping with panics as an independent variable were largely unsuccessful.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 333492     DOI: 10.1017/s0033291700004384

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  5 in total

Review 1.  Current status of beta-blocking drugs in the treatment of anxiety disorders.

Authors:  P Tyrer
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

2.  Use of beta-blocking drugs in psychiatry and neurology.

Authors:  P J Tyrer
Journal:  Drugs       Date:  1980-10       Impact factor: 9.546

Review 3.  The utility of the panic disorder concept.

Authors:  D F Klein; H M Klein
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

Review 4.  Pharmacological enhancement of fear reduction: preclinical models.

Authors:  Bronwyn M Graham; Julia M Langton; Rick Richardson
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

5.  Angiotensin involvement in trauma processing-exploring candidate neurocognitive mechanisms of preventing post-traumatic stress symptoms.

Authors:  Lorika Shkreli; Marcella Lydia Woud; Roger Ramsbottom; Aleksandra Ewa Rupietta; Gerd Thomas Waldhauser; Robert Kumsta; Andrea Reinecke
Journal:  Neuropsychopharmacology       Date:  2019-10-26       Impact factor: 7.853

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.